Our Team

Eric WeisblumCEO
Eric Weisblum is the founder and Chief Executive Officer of Silo Pharma Inc. Prior to Silo Pharma Mr. Weisblum was a private investor and advisor to several of his portfolio companies. Mr. Weisblum has experience in both inlicensing therapeutic assets and assisting in their development. As a result, Mr. Weisblum brings with him nearly 20 years of experience in structuring and trading financial instruments. Mr. Weisblum is involved in his community and can often be found on the soccer field with his family of four. He holds a B.A. from the University of Hartford’s Barney School of Business.
Dr. Kevin MuñozBoard Member
Dr. Kevin Muñoz, 44, was appointed to the Board of Directors on October 1, 2020. Dr. Munoz recently began teaching Biomedical Sciences and medical intervention for the Passaic County Technical Institute. Dr. Muñoz served as Director of Operations at Physical Medicine and Rehabilitation where he has responsibility for the day-to-day management of all office operations with a focus on ensuring and increasing patient satisfaction Dr. Munoz takes pride in giving each patient individualized attention. Prior to that, he led the configuration efforts during an enterprise-wide implementation of application software that also included streamlining and improving business processes. Kevin began his career with Harlem Health Promotion Center in New York City as a Research Assistant where he was responsible for data collection and interpretation. Dr. Muñoz earned a Bachelor of Science from the University of Michigan where he graduated with distinction and a Doctor of Medicine from Xavier University School of Medicine, Aruba NA.
Wayne LinsleyBoard Member
Wayne D. Linsley, 65, has served as a director of the Company since January 2020. Mr. Linsley has been in business management for over 40 years. He possesses a wide and varied skillset including sales and sales management, finance (for both public and private companies), accounting, audit support and financial reporting. He has a bachelor’s in business administration from Siena College in Loudonville, NY.

From 2009 to September 2021 he worked for a financial reporting firm that works with publicly traded companies. He has extensive knowledge of financial statements, MD&A, SEC Filings (10K, 10Q, 8K, etc.) Edgar, etc. He often negotiates on behalf of clients in such areas as audit fees, transfer agents, Edgar companies, etc. He currently serves as an independent director for two other public companies.
Dr. Josh Woolley MD/PhDScientific Advisor
Dr. Josh Woolley MD/PhD is an Associate Professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco (UCSF). He is also a licensed psychiatrist on staff at the San Francisco Veterans Affairs Medical Center (SFVAMC). He received both his MD and his PhD in Neuroscience from UCSF and completed his psychiatry residency training at UCSF. Dr. Woolley is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders (BAND) Laboratory. The mission of the BAND Lab is to understand why people with mental illnesses, including schizophrenia, posttraumatic stress disorder, mood disorders, and substance use disorders, have trouble with social connection, and to develop and test novel treatments for these deficits. His laboratory is actively investigating psilocybin therapy for multiple disorders including major depressive disorder, bipolar depression, chronic pain, and mood symptoms associated with Parkinson's Disease.
Dr. James Kuo, M.D., MBAVice President of R&D
Dr. James (Jim) Kuo currently serves as Managing Director of Athena Bioventures in La Jolla, CA. He is an experienced biotech industry executive and investor who brings financial and management experience to the company. During his career, he has held executive positions in private as well as listed bioscience companies in the U.S., Canada, and Europe. He currently serves as Chairman of the Board of ImmunoPrecise Antibodies and a board director of Tryp Therapeutics. He previously served as CEO of Tryp Therapeutics, Synthetic Biologics, BioMicro Systems, and Discovery Laboratories. Prior to that, Dr. Kuo was Associate Director in Corporate Licensing and Development at Pfizer and Managing Director of HealthCare Ventures, a $378 million venture fund. He received his MD from the University of Pennsylvania School of Medicine and his MBA from the Wharton School of Business.
Charles B. Nemeroff, M.D., Ph.D.Scientific Advisor
Charles Nemeroff is chair and professor with the Department of Psychiatry and Behavioral Sciences. He also directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences.

Prior to joining Dell Med, Nemeroff was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine in Miami, Florida.

He received his medical degree and doctorate degrees in neurobiology from the University of North Carolina (UNC) School of Medicine. After psychiatry residency training at UNC and Duke University, he held faculty positions at Duke University Medical Center and at Emory University School of Medicine before relocating to the University of Miami in 2009.

He has served as president of the American College of Psychiatrists (ACP) and the American College of Neuropsychopharmacology (ACNP), and sits on the Scientific Advisory Board of the Brain and Behavior Research Foundation. He is President-elect of the Anxiety and Depression Association of America (ADAA). He is a member of the National Academy of Medicine.
Daniel RyweckCFO
Certified Public Accountant. Formerly chief compliance officer of Mill City Ventures III Ltd, interim chief financial officer of Sun BioPharma, Inc., and director of Dala Petroleum Corp.